false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Changing the standard of care in 2nd line recurren ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this webinar, Dr. Brian Slomovitz discusses the results of the Innovative 301 trial, a phase 3 study evaluating the use of tezotamab vidotin (TV) in the second or third-line management of recurrent or metastatic cervical cancer. The trial showed that TV demonstrated a statistically significant and clinically meaningful improvement in overall survival, with a 30% reduction in the risk of death compared to investigative choice chemotherapy. The median overall survival in the TV arm was 11.5 months compared to 9.5 months in the chemotherapy arm. Progression-free survival was also improved with TV, with a 33% decrease in the risk of recurrence or death. TV was generally well-tolerated, with manageable side effects. The study concluded that TV should be considered as a potential new standard of care for patients with recurrent or metastatic cervical cancer who have progressed after first-line systemic therapy.
Keywords
webinar
Dr. Brian Slomovitz
tezotamab vidotin
cervical cancer
overall survival
progression-free survival
Contact
education@igcs.org
for assistance.
×